How are prolactinomas treated in patients who cannot tolerate BEC?

Updated: Mar 25, 2018
  • Author: Venkatesh Babu Segu, MD, MBBS, DM; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print

Other medical treatments for prolactinomas are available for patients who do not respond to BEC or for those who cannot tolerate the drug. Cabergoline, an ergot derivative, is a long-acting DA agonist and is available in the United States.

In those patients with DA agonist–resistant prolactinomas (DARPs) having persistent hyperprolactinemia despite surgical debulking, with or without radiotherapy, temozolomide, a chemotherapeutic alkylating agent, has been recommended. [10]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!